Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorUniversity of Basel
About this trial
Cognitive deficits, including working memory deficits, are often present in depression and there are currently no effective pharmacological treatments targeting working memory deficits. Papassotiropoulos et al. (2024) has recently demonstrated that fampridine, a potassium channel blocker, can enhance working memory in healthy individuals with lower baseline performance, suggesting it may hold potential for addressing cognitive deficits in clinical populations. The primary aim of this study is to evaluate whether fampridine improves working memory performance in mild to moderate depression
Eligibility criteria
Qualifiers
Male or female
Major depressive episode confirmed by the Mini-DIPS. Currently mild to moderate (MADRS: 7-30).
Normotensive (BP: 90/60mmHg - 140/90mmHg). Sufficiently treated hypertensive subjects will be included.
BMI: 19 - 34,9 kg/m2
Disqualifiers
Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to 4-aminopyridine
Use of potassium channel blockers within the last 3 months
Treatment with OCT 2 inhibitors and -substrates (e.g. cimetidine, propranolol)
Treatment with antidepressants or antipsychotics within the last 3 months and throughout the study period
Trial design
Treatments tested in this trial
- Fampridine SR
- Placebo
Treatment groups
38 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Basel
Lead sponsor
Clinical Trial Unit, University Hospital Basel, Switzerland
Collaborator
Source ClinicalTrials.gov